Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Galera Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10596)・商品コード:DATA904C10596
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:25
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥83,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Galera Therapeutics Inc (Galera Therapeutics) is a clinical-stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selective small molecule superoxide dismutase enzyme mimetic that quickly converts superoxide free radical molecules to hydrogen peroxide and oxygen. Galera Therapeutic’s dismutase mimetics copies the human superoxide dismutase enzyme activities and overcome the deficiency. The company’s research and development unit concentrates on protection from normal tissue damage and direct anti-cancer therapy. Galera Therapeutics is headquartered in Malvern, Pennsylvania, the US.

Galera Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 10
Galera Therapeutics Raises Additional USD15 Million in Series B Financing 12
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 13
Galera Therapeutics Raises USD37 Million in Series B Financing 14
Galera Therapeutics Raises USD4.74 Million In Venture Financing 15
Galera Therapeutics Raises US$11 Million In Series A Financing 16
Asset Transactions 17
Galera Therapeutics Enters into Royalty Agreement with Clarus Ventures 17
Galera Therapeutics Inc – Key Competitors 18
Galera Therapeutics Inc – Key Employees 19
Galera Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Product Approvals 21
Jul 31, 2017: Galera Therapeutics Announces Promising Innovative Medicines Designation from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for GC4419 for the Reduction of Oral Mucositis in Head and Neck Cancer Patients 21
Clinical Trials 22
Jan 04, 2018: Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 to be Presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium 22
Dec 18, 2017: Galera Therapeutics Reports Statistically Significant Results in a 223-Patient Phase 2b Trial of GC4419 for Severe Oral Mucositis in Patients with Head and Neck Cancer 23
Jun 15, 2017: Galera Therapeutics Completes Enrollment in Phase 2b Clinical Trial with Lead Compound GC4419 for Treatment of Oral Mucositis 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 10
Galera Therapeutics Raises Additional USD15 Million in Series B Financing 12
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 13
Galera Therapeutics Raises USD37 Million in Series B Financing 14
Galera Therapeutics Raises USD4.74 Million In Venture Financing 15
Galera Therapeutics Raises US$11 Million In Series A Financing 16
Galera Therapeutics Enters into Royalty Agreement with Clarus Ventures 17
Galera Therapeutics Inc, Key Competitors 18
Galera Therapeutics Inc, Key Employees 19

List of Figures
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10596)販売に関する免責事項を必ずご確認ください。
★調査レポート[Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆